Neuroprotective Effect of Naloxone in Inflammation-Mediated Dopaminergic Neurodegeneration - Drugs of Abuse: Neurological Reviews and Protocols - page 48

4. Roy, S. and Loh, H. (1996) Effects of opioids on the immune system. Neurochem.
Res. 21, 1375-1386.
5. Groneberg, D. A. and Fischer, A. (2001) Endogenous opioids as mediators of
asthma. Pulm. Pharmacol. Ther. 14, 383-389.
6. Gianoulakis, C. (2001) Infl uence of the endogenous opioid system on high alcohol
consumption and genetic predisposition to alcoholism. J. Psychiatry Neurosci.
26, 304-318.
7. Volpicelli, J. R. (2001) Alcohol abuse and alcoholism: an overview. J. Clin.
Psychiatry 20, 4-10.
8. Kieffer, B. L. (1995) Recent advances in molecular recognition and signal
transduction of active peptides: receptors for opioid peptides. Cell. Mol. Neurobiol.
15, 615-635.
9. Minami, M. and Satoh, M. (1995) Molecular biology of the opioid receptors:
structures, functions and distributions. Neurosci. Res. 23, 121-145.
10. Jordan, B. A., Cvejic, S., and Devi, L. A. (2000) Opioids and their complicated
receptor complexes. Neuropsychopharmacology 23, S5-S18.
11. Knapp, R. J., Malatynska, E., Collins, N., et al. (1995) Molecular biology and
pharmacology of cloned opioid receptors. FA S EB J. 9, 516-525.
12. Iijima, I., Minamikawa, J-I., Jacobsen, A. E., Brossi, A., and Rice, K. E. (1978)
Studies in the (+)-morphinin series-5. Synthesis and biological properties of
(+)-naloxone. J. Med. Chem. 21, 398-400.
13. Marcoli, M., Ricevuti, G., Mazzone, A., Pasotti, D., Lecchini, S., and Frigo, G. M.
(1989) A stereoselective blockade by naloxone of opioid and non-opioid-induced
granulocyte activation. Int. J. Immunopharmacol. 11, 57-61.
14. Ward, J., Hall, W., and Mattick, R. P. (1999) Role of maintenance treatment in
opioid dependence. Lancet 353, 221-226.
15. de Zwaan, M. and Mitchell, J. E. (1992) Opiate antagonists and eating behavior
in humans: a review. J Clin. Pharmacol. 32, 1060-1072.
16. Anton, R. F. (2001) Pharmacologic approaches to the management of alcoholism.
J. Clin. Psychiatry 20, 11-17.
17. Seidl, E. C. (2000) Promising pharmacological agents in the management of acute
spinal cord injury. Pharm. Pract. Manag. 20, 21-27.
18. Hosobuchi, T., Baskin, D. S., and Woo, S. K. (1982) Reversal of induced ischemic
neurologic deficit in gerbil by the opiate antagonist naloxone. Science 215,
69-71.
19. Fallis, R. J., Fisher, M., and Lobo, R. A. (1983) A double blind trial of naloxone
in the treatment of stroke. Stroke 15, 627-629.
20. Holaday, J. W. and Macolm, D. S. (1986) Endogenous opioids and their antagonist
in endotoxic shock, in 9th International Congress of Infectious and Parasitic
Diseases: Bacterial Infection, Antibacterial Chemotherapy (Marget, W., Lang, W.,
and Gabler-Sanberger, E., eds.), pp. 425-435, Munich.
21. Chen, C., Cheng, J. F. C., Liao, S. L., Chen, W. Y., Lin, N. N., and Kuo, J. S. (2000)
Effects of naloxone on lactate, pyruvate metabolism and antioxidant enzyme
activity in rat cerebral ischemia/reperfusion. Neurosci. Lett. 287, 113-116.